Sibylla Biotech
PrivateLast Round
Series A
Oct 4, 2022
Total Funding Raised
$22.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sibylla Biotech is a biotechnology company that develops small molecule therapeutics using its proprietary PPI-FIT platform to induce targeted protein degradation by interfering with protein folding pathways.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sibylla Biotech Comparables
Compare Sibylla Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Charm Therapeutics | 83% | |
| Peptone | 83% | |
| SyntheX | 78% |
Sibylla Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 4, 2022 | ||||
| Seed | Jul 1, 2019 |
Key People
Founding team and executive leadership
Sibylla Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Vertis SGR | Series A |
| Seroba Life Sciences | Series A |
| 3B FUTURE Health Fund | Series A |
| Indaco Venture Partners SGR | Series A |
| VI Partners | Series A |
| V-Bio Ventures | Series A |
| Claris Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 61% MoM, reaching 1K.
- Jun 17, 2026
Monthly visitors increased 82% MoM, reaching 1K.
Recent news
Latest coverage and updates
- hiresOct 13, 2026
Sibylla Biotech S.r.l. appoints Usman Azam as Chief Executive Officer in Italy on Oct 13th '26
- promotesOct 13, 2026
Sibylla Biotech S.r.l. promotes Elena Ardini, MSc, to Chief Scientific Officer in Italy on Oct 13th '26
- hiresOct 13, 2026
Sibylla Biotech S.r.l. appoints Gianluca Fuggetta as Chief Financial Officer in Italy on Oct 13th '26, expanding its executive leadership team.
Sibylla Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sibylla Biotech's valuation, stock price, and market status.
Is Sibylla Biotech a public or private company?
Sibylla Biotech is a private company.
What is the current stock price of Sibylla Biotech?
Sibylla Biotech is a private company, so its shares have no public market price. Caplight tracks Sibylla Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sibylla Biotech worth (valuation)?
Valuation information for Sibylla Biotech is not publicly available.
Can I buy Sibylla Biotech stock?
Sibylla Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sibylla Biotech's last funding round?
Sibylla Biotech's most recent funding round was Series A on October 4, 2022.
Who are the main investors in Sibylla Biotech?
Key investors in Sibylla Biotech include V-Bio Ventures.
Will Sibylla Biotech IPO soon?
No public IPO plans have been announced for Sibylla Biotech.
How can I track Sibylla Biotech secondary market activity?
Caplight tracks bids, offers, and trades in Sibylla Biotech's shares on secondary markets.